FDA approval expands earlier use of Enhertu for metastatic breast cancer

by

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow breast cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *